Bloodless medicine and surgery

Journal of Intensive Care Medicine

Volumn 14, Issue 1, 1999, Pages 20-33

  Savarese, Diane ^a,b   Waitkus, Heidi ^a   Stewart, F Marc ^a   Callery, Mark ^a  

^a University of Massachusetts   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; DISEASE TRANSMISSION; HUMAN; INFECTION RISK; PRIORITY JOURNAL; RELIGION; REVIEW; RISK FACTOR; TREATMENT PLANNING;

EID: 0032905941     PISSN: 08850666     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1489.1999.00020.x     Document Type: Review

References (98)

1. Klein HG. Allogeneic transfusion risks in the surgical patient. Am J Surg 1995;170:21S-26S
2. Jackson RM, Rice DH. Blood transfusion and recurrence in head and neck cancer. Ann Otol Rhinol Laryngol 1989;98: 171-173
3. Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg 1993;80:427-432
4. Vamvakas EC. Perioperative blood transfusion and cancer recurrence: metaanalysis for explanation. Transfusion 1995; 35:760-768
5. Busch ORC, Marquet RL, Hop WCJ, et al. Colorectal cancer recurrence and perioperative blood transfusions: a critical appraisal. Semin Surg Oncol 1994;10:195-199
6. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994;12:1859-1861
7. Houbiers JGA, Van Brand A, de Watering LMG, et al. Randomized controlled trial comparing transfusion of leucocytedepleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994;344:573-578
8. Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998;279:217-221
9. Fowler NO, Homes JC. Blood viscosity and cardiac output in acute experimental anemia. J Appl Physiol 1975;39:453-456
10. Carson JL, Duff A, Berlin JA, et al. Perioperative blood transfusion and postoperative mortality. JAMA 1998;279:199-205
11. Erslev AJ, Caro J, Miller O, et al. Plasma erythropoietin in health and disease. Ann Clin Lab Sci 1980;10:250-257
12. Miyake T, Kung C, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977;252:5558-5564
13. Mufson RA, Gesner TG. Binding and internalization of recombinant human erythropoietin in murine erythroid precursor cells. Blood 1987;69:1485-1489
14. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end stage renal disease with recombinant human erythropoietin. N Engl J Med 1987;316:73-78
15. Valeri CR, Crowley JP, Loscalzo J. The red cell transfusion trigger: Has a sin of commission now become a sin of omission? Transfusion 1998;38:602-610
16. Kitchens CS. Are transfusions overrated? Surgical outcome of Jehovah's Witnesses. Am J Med 1993;94:117-119
17. Carson JL, Poses RM, Spence RK, et al. Severity of anemia and operative mortality and morbidity. Lancet 1988;1:727-729
18. Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood: the experience with Jehovah's Witnesses. Transfusion 1994;34:396-401
19. Spence RK, Carson JA, Poses R. Elective surgery without transfusion: influence of preoperative hemoglobin level and blood loss on mortality. Am J Surg 1990;159:320-324
20. Christopherson R, Frank S, Norris E, et al. Low postoperative hematocrit is associated with cardiac ischemia in high risk patients. Anesthesiology 1991;75:A99
21. Consensus Conference. Perioperative red blood cell transfusion. JAMA 1988;260:2700-2704
22. Silberstein LE, Kruskall MS, Stehling LC, et al. Strategies for the review of transfusion practices. JAMA 1989;262: 1993-1997
23. Anonymous. Practice strategies for elective red blood cell transfusion. Clin Guide Am College Physicians 1992;116: 403-406
24. Spence RK. Surgical red blood cell transfusion practice policies. Am J Surg 1995;170:3S-15S
25. Spence RK, McCoy S, Costabile J, et al. Fluosol DA-20 in the treatment of severe anemia: randomized controlled study of 46 patients. Crit Care Med 1990;18:1227-1230
26. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements. N Engl J Med 1986;314:1233-1235
27. Christenson JT, Maurice J, Simonet F, et al. Normothermic versus hypothermie perfusion during primary coronary artery bypass grafting. Cardiovasc Surg 1995;3:519-524
28. Salem M, Chernow B, Burke R, et al. Bedside diagnostic testing: its precision, rapidity, and utility in blood preservation. Crit Care Med 1991;19:584
29. Silver MJ, Jubran H, Stein S, et al. Evaluation of a new blood-conserving arterial line system for patients in intensive care units. Crit Care Med 1993;21:507-511
30. Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids, drugs, or miracle solutions? Anesth Analg 1996;82:390-405
31. Keating EM. Current options and approaches for blood management in orthopaedic surgery. J Bone Joint Surg 1998; 80A:750-762
32. Gould SA, Rosen AL, Sehgal LR, et al. Fluosol DA as a red cell substituted in acute anemia. N Engl J Med 1986;314: 1653-1656
33. Keipert PE. Use of oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. Artif Cells Blood Substit Immobil Biotechnol 1995;23: 381-394
34. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthoped 1996;25:544-552
35. Rutherford CJ, Schneider T, Dempsey H, et al. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability. Am J Med 1994;96:139-145
36. DeAndrade JR, Jove M, Landon G, et al. Baseline hemoglobin as predictor of risk of transfusion and response to epoietin alfa in orthopedic surgery patients. Am J Orthoped 1996; 25:533-542
37. Brugnara C, Chambers LA, Malynn E, et al. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin:iron-deficient erythropoiesis in iron-replete subjects. Blood 1993;81:956-963
38. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-1699
39. Auerbach M, Witt D, Toler W, et al. Clinical use of the total dose infusion of iron dextran. J Lab Clin Med 1988;111:566-570
40. Toy PTCY, Menozzi D, Strauss RG, et al. Efficacy of preoperative donation of blood for autologous use in radical prostatectomy. Transfusion 1993;33:721-724
41. Ness PM, Bourke DL, Walsh PK. A randomized trial of perioperative hemodilution vs transfusion of preoperatively deposited autologous blood in elective surgery. Transfusion 1991;32:226-230
42. Dzik WH, Fleisher AG, Ciavarella D, et al. Safety and efficacy of autologous blood donation before elective aortic valve operation. Ann Thorac Surg 1992;54:1177-1181
43. Mercuriali F, Zanella G, Barosi G, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1992;33:55-60
44. Kyo S, Omoto R, Hirashima K, et al. Effect of human recombinant erythropoietin on reduction of homologous blood transfusion in open heart surgery. Circulation 1992;86(suppl II):413-418
45. Speiss BD, Sassetti R, McCarthy R, et al. Autologous blood donation: hemodynamics in a high-risk patient population. Transfusion 1992;32:17-22
46. Aubuchon JP, Popovsky MA. The safety of preoperative autologous blood donation in the non-hospital setting. Transfusion 1991;31:513-517
47. Etchason J, Petz L, Keeler E, et al. The cost-effectiveness of preoperative autologous blood donations. N Engl J Med 1995;332:719-724
48. Monk TG, Goodnough LT. Blood conservation strategies to minimize allogeneic blood loss in urologic surgery. Am J Surg 1995;170:69S-73S
49. Goodnough LT, Grishaber JE, Birkmyer JD, et al. Efficacy and cost effectiveness of autologous blood predeposit in patients undergoing radical prostatecotomy procedure. Urology 1994;44:226-231
50. Domen RE. Preoperative autologous blood donation: clinical, economic, and ethical issues. Cleve Clin J Med 1996;63: 295-300
51. Blumberg N, Kirkley SA, Heal JM. A cost analysis of autologous and allogeneic transfusions in hip-replacement surgery. Am J Surg 1996;171:324-330
52. Laks H, Pilon RN, Klovekorn WP. Acute hemodilution: its effects on hemodynamics and oxygen transport in anesthetized man. Ann Surg 1974;180:103-110
53. Rose D, Coutsoftides T. Intraoperative normovolemic hemodilution. J Surg Res 1981;31:375-381
54. Monk TG, Goodnough LT, Birkmeyer JD. Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy. Transfusion 1995;35: 559-565
55. Bryson GL, Laupacis A, Wells GA. Does acute normovolemic hemodilution reduce perioperative allogeneic transfusion? A meta-analysis. Anesth Analg 1998;86:9-15
56. Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood 1997;89:411-418
57. Monk TG, Goodnough LT, Brecher ME, et al. Acute normovolemic hemodilution can replace preoperative autologous blood donation as a standard of care for autologous blood procurement in radical prostatectomy. Anesth Analg 1997; 85:953-958
58. Spahn DR, Schmid ER, Burkhardt S, et al. Hemodilution tolerance in patients with coronary artery disease who are receiving chronic B-adrenergic blocker therapy. Anesth Analg 1996;82:687-694
59. Spence RK, Alexander JB, DelRossi AJ, et al. Transfusion guidelines for cardiovascular surgery: lessons learned from operations in Jehovah's Witnesses. J Vase Surg 1992;16: 825-831
60. Cooley DA. Conservation of blood during cardiovascular surgery. Am J Surg 1995;170:53S-59S
61. Karczewski DM, Lema MJ, Glaves D. The efficiency of an autotransfusion system for tumor cell removal from blood salvaged during cancer surgery. Anesth Analg 1994;78: 1131-1135
62. Dale RF, Kipling RM, Smith MF, et al. Separation of malignant cells during autotransfusion. Br J Surg 1988;75:581-586
63. Miller GV, Ramsden CW, Primrose JN. Autologous transfusion: an alternative to transfusion with banked blood during surgery for cancer. Br J Surg 1991;78:713-715
64. Edelman MJ, Potter PJ, Mahaffey KG, et al. The potential reintroduction of tumor cells during intraoperative blood salvage: reduction of risk with use of the RC-400 leucocyte depletion filter. Urology 1996;47:179-181
65. Noon GP, Jones J, Fehir K, et al. Use of preoperatively obtained platelets and plasma in patients undergoing cardiopulmonary bypass. J Clin Aspheresis 1990;5:91-96
66. Christenson JT. Platelet pheresis before re-do CABG diminished excessive blood transfusion. Ann Thorac Surg 1996; 62:1373-1379
67. Mohr R, Goor DA, Yellin A, et al. Fresh blood units contain large potent platelets that improve hemostasis after open heart operations. Ann Thorac Surg 1992;53:650-654
68. Stover EP. Platelet-rich plasma pheresis with therapeutic platelet yield reduces allogeneic red blood cell and platelet transfusions in high risk cardiac surgery. Anesthesiology 1996;85:968
69. Nelson CL, Fontenot HJ. Ten strategies to reduce blood loss in orthopedic surgery. Am J Surg 1995;170:64S-68S
70. Reed RLI, Johnson TD, Hudson JD, et al. The disparity between hypothermic coagulopathy and clotting studies. J Trauma 1992;33:465-470
71. Tanaka J, Takao M, Yada I, et al. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Vase Anesth 1989; 3:181-188
72. Bidstrup BP, Harrison J, Royston D, et al. Aprotinin therapy in cardiac surgery: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993;55:971-976
73. Havel MP, Griesmacher A, Weigel G, et al. Aprotonin increases release of von Willebrand factor in cultured human umbilical vein endothelial cells. Surgery 1992; 112:573-577
74. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339: 245-253
75. Wilson JM, Bower LK, Fackler JC, et al. Aminocaproic acid decreases the incidence of intracranial hemorrhage and other hemorrhagic complications of ECMO. J Pediatr Surg 1993;28:536-541
76. VanderSalm TJ. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 1996;112:1098-1107
77. Bartholomew JR, Salgia R, Bell WR. Control of bleeding with immune and non-immune thrombocytopenia with aminocaproic acid. Arch Int Med 1989;149:1959-1961
78. Ereth MH, Oliver WC, Santrach PJ. Perioperative interventions to decrease transfusion of allogeneic blood products. Mayo Clin Proc 1994;69:575-586
79. Horrow JC, Van Riper DF, Strong MD, et al. Hemostatic effects of tranexamic acid and desmopression during cardiac surgery. Circulation 1991;84:2063-2070
80. Mannucci PM. Desmopression: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988;72:1449-1455
81. Guay J, Reinberg C, Poitras B, et al. A trial of desmopression to reduce blood loss in patients undergoing spinal fusion for idiopathic scoliosis. Anesth Analg 1992;75:405-410
82. Hackmann T, Gascoyne RD, Naiman SC, et al. A trial of desmopression (1-desamino-8d-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 1989;321:1437-1443
83. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58:1580-1588
84. Grim PS, Gottlieb LJ, Boddie A, et al. Hyperbaric oxygen therapy. JAMA 1990;263:2216-2220
85. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 1990;322:1689-1692
86. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoietin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-1234
87. Kaufman DB, Sutherland DER, Fryd DS, et al. A single center experience of renal transplantation in thirteen Jehovah's Witnesses. Transplantation 1988;45:1045-1049
88. Benson K. Management of the Jehovah's Witness oncology patient: perspective of the transfusion service. Cancer Control J 1997;2:552-556
89. Fujita H, Marute A, Koharazawa H, et al. Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. Int J Hematol 1997;65:415-416
90. Goldberg SL, Chan CSP, Dawkins FW, et al. Should Jehovah's Witnesses be denied intensive chemotherapy for acute leukemia? N Engl J Med 1990;322:777-778
91. Dainer PM, Knupp CL, Sartiano GP. Low dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. Am J Hematol 1992;40:156-161.
92. Nousiainen T, Jantunen E, Lahtinen R. Jehovah's Witnesses and acute leukemia. Am J Hematol 1993;43:158-163
93. Boggs DR. Jehovah's Witnesses with leukemia. Hosp Prac (Off Ed) 1985:20:92-98
94. Cullis JO, Smith AG. Jehovah's Witnesses with leukemia. Lancet 1990;336:1075-1076
95. Hargis JG, Waddell DJ, Diehl L, et al. Induction chemotherapy in Jehovah's Witnesses with leukemia. Lancet 1990;336: 563-564
96. Estrin JT, Ford PA, Henry DH, et al. Erythropoietin permits high dose chemotherapy with peripheral blood stem-cell transplant for a Jehovah's Witness. Am J Hematol 1997;55: 51-54
97. Vernon S. Center for Bloodless Medicine and Surgery. An Institutional Effect. 1996. Poster presentation, IVth Annual Symposium, Critical Issues in Surgery, St. Thomas, U.S. Virgin Islands, December 2-4, 1996
98. Helm RE, Rosengart TK, Gomez M, et al. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 1998;65: 125-136